Persistent Postural-Perceptual Dizziness (PPPD): A Common, Characteristic and Treatable Cause of Chronic Dizziness
Pract Neurol 18:5-13, Popkirov, S.,et al, 2018
Adult Attention Deficit - Hyperactivity Disorder
NEJM 369:1935-1944, Volkow, N.D. & Swanson, J.M., 2013
Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary
Neurol 98:31-43, Price, R.,et al, 2022
Distal Symmetric Polyneuropathy in 2020
JAMA 324:90-92, Callaghan, B.C.,et al, 2020
Diabetic Sensory and Motor Neuropathy
NEJM 374:1455-1464, Vinik, A.I.,et al, 2016
Diagnosis and Treatment of Tourette Syndrome
Neurol 87:e65-e67, Hirschtritt, M.E.,et al, 2016
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Obsessive-Compulsive Disorder
BMJ 348:g2183, Veale, D.,et al, 2014
Fibromyalgia
JAMA 311:1547-1555, Clauw, D.J., 2014
Selective Serotonin Reuptake Inhibitors May be Helpful in Most Patients with Stroke
Stroke 43:3150-3151,3154, Chollet, F., 2012
Should Every Patient with Stroke be on Selective Serotonin Reuptake Inhibitors?
Stroke 43:3152-3153,3154, Marshall, R.S., 2012
Tricyclic Antidepressants and Headaches: Systematic Review and Meta-Analysis
BMJ 341:c5222, Jackson,J.L.,et al, 2010
Diagnosis and Management of Neuropathic Pain
BMJ 339:391-395, Freynhagen,R. &Bennett,M.I., 2009
Narrative Review: Reversible Cerebral Vasoconstriction Syndromes
Ann Intern Med 146:34-44, Calabrese,L.H.,et al, 2007
Chronic Daily Headache
NEJM 354:158-165, Dodick,D.W., 2006
Hyponatremia in Neurologic Patients: Consequences and Approaches to Treatment
The Neurologist 12:117-126, Diringer,M.N. &Zazulia,A., 2006
Obsessive-Compulsive Disorder
BMJ 333:424-429, Heyman,I.,et al, 2006
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
A 47-Year-Old Woman with Tension-Type Headaches
JAMA 286:960-966, Welch,K.M.A., 2001
Depression in Parkinson's Disease
BMJ 320:1287-1288, Allain,H.,et al, 2000
Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Antidepressants and Chronic Pain
BMJ 314:763-764, McQuay,H.J.&Moore,R.A., 1997
Severe Pathological Crying After Left Anterior Choroidal Artery Infarct
Stroke 28:1464-1466, Derex,L.,et al, 1997
Clinical Features and Pharmacologic Treatment of Behavioral Symptoms of Alzheimer's Disease
Neurol 48 (Suppl 6) :S17-S24997., Borson,S.&Raskind,M.A., 1997
Diagnosis and Treatment of Alzheimer Disease and Related Disorders
JAMA 278:1363-1371, Small,G.W.,et al, 1997
Effects of Fluoxetine and Maprotiline on Functional Recovery in Poststroke Hemiplegic Pts Undergoing Rehab Therapy
Stroke 27:1211-1214, Dam,M.,et al, 1996
Serotonin Syndrome
Neurol 45:219-223, Bodner,R.A.,et al, 1995
The Narcolpetic Syndrome
JNNP 59:221-224, Parkes,J.D.,et al, 1995
Anticonvulsant Effect of Fluoxetine in Humans
Neurol 45:1926-1927, Favale,E.,et al, 1995
Increase of Parkinson Disability after Fluoxetine Medication
Neurol 43:211-213, Steur,E.N.H.J., 1993
Polymyalgia Rheumatica
NEJM 394:1097-1109, Dejaco,C.,et al, 2026
Asundexian for Secondary Stroke Prevention
NEJM 394:1467-1479, 1540, Sharm,M.,et al, 2026
A 28-Year-Old Man with Seizures and Thalamic Lesions
Neurol 106:e218065, Santos-Rojo,A.B.,et al, 2026
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025
Myasthenia Gravis - Redemption for B-Cell Depletion
NEJM 392:2382-2384, Wolfe,G.I. & Shelly,S., 2025
Efficacy and Safety of Selimetinib in Adults with Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas (KOMET): A Multcentre, International, Randomised Placebo-Controlled, Parallel, Double-Blind, Phase 3 Study
Lancet 405:2217-2230, Chen,A.P.,et al, 2025
Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study
Ann Neurol 98:80-92, Guo,K.,et al, 2025
Collaboration on the Optimal Timing of Anticoagulation after Ischaemic Stroke and Atrial Fibrillation:A Systematic Review and Prospective Individual Participant Data Meta-Analysis of Randomised Controlled Trials (CATALYST)
Lancet 406:43-51, Dehbi,K-M.,et al, 2025